|
業務類別
|
-- |
|
業務概覽
|
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing productsfor the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function. |
| 公司地址
| No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206 |
| 電話號碼
| +86 1066609999 |
| 傳真號碼
| +86 1060702992 |
| 公司網頁
| https://www.innocarepharma.com |
| 員工數量
| 1259 |
| Dr. Jisong Cui, PhD |
Chairman of the Board and Chief Executive Officer |
-- |
26/03/2026 |
| Dr. Renbin Zhao, PhD |
Director and Senior Vice President, Hematologic Oncology Medical Research and Clinical Development |
-- |
26/03/2026 |
|
|
| Dr. Jisong Cui, PhD |
Chairman of the Board and Chief Executive Officer |
26/03/2026 |
| Dr. Renbin Zhao, PhD |
Director and Senior Vice President, Hematologic Oncology Medical Research and Clinical Development |
26/03/2026 |
| Dr. Yigong Shi, PhD |
Director |
26/03/2026 |
| Mr. Ronggang Xie |
Director |
26/03/2026 |
| Ms. Lan Hu |
Independent Director |
26/03/2026 |
| Dr. Dandan Dong, PhD |
Independent Director |
26/03/2026 |
| Professor Kunliang Guan |
Independent Director |
26/03/2026 |
|
|
|
|
